{"id":"https://genegraph.clinicalgenome.org/r/5dc53c97-cb65-4d12-bb90-9240391ac024v1.0","type":"EvidenceStrengthAssertion","dc:description":"GALNT3 was first reported in relation to autosomal recessive Tumoral calcinosis, hyperphosphatemic, familial, 1 [HFTC] (MONDO:100252) in 2004 (N Topaz O et al., 2004, PMID:15133511). HFTC is a rare autosomal recessive metabolic disorder characterized by the progressive deposition of basic calcium phosphate crystals in periarticular spaces, soft tissues, and sometimes bone. The disease can be caused by recessive mutations in at least two different genes: GalNAc transferase 3 (GALNT3), encoding a glycosyltransferase that initiates mucin-type O-glycosylation, and fibroblast growth factor 23 (FGF23), which encodes a regulator of phosphate circulating levels. The biochemical hallmark of tumoral calcinosis is hyperphosphatemia caused by increased renal absorption of phosphate due to loss-of-function mutations in the FGF23 (OMIM:605380) or GALNT3 gene (Kato et al., 2006, PMID:16638743). The GALNT3 gene provides instructions for making a protein called ppGalNacT3, which is found in many types of cells. This protein plays a leading role in regulating phosphate levels within the body (phosphate homeostasis). Among its many functions, phosphate plays a critical role in the formation and growth of bones in childhood and helps maintain bone strength in adults. Phosphate levels are controlled by the kidneys. The kidneys normally rid the body of excess phosphate by excreting it in urine, and they reabsorb this mineral into the bloodstream when more is needed. \n\n \n\nMore than 220 unique variants (e.g., synonymous, missense, in-frame indel, nonsense, frameshift) have been reported in humans by ClinVar. Evidence supporting this gene-disease relationship includes case-level data and experimental data. Seven variants (1 nonsense, 1 missense, 2 splice donors, 1 splice acceptor, 1 frame-shift and 1 intron) that have been reported in approximately 6 probands in 3 publications (Topaz O et al., 2004, PMID:15133511; Ichikawa S et al., 2005, PMID: 15687324; and Ichikawa S et al. 2010; PMID:20358599), are included in this curation. More evidence is available in the literature, but the maximum score for genetic evidence (12 pts.) has been reached. This gene-disease relationship is also supported by protein interaction, and animal models studies (Kato et al., 2006, PMID: 16638743; Ichikawa et al., 2009, PMID: 19213845; Ichikawa et al., 2014, PMID: 25051439). In summary, there is definitive evidence to support the relationship between GALNT3 and Tumoral calcinosis, hyperphosphatemic, familial, 1. This has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time. This classification was approved by the ClinGen Congenital Disorders of Glycosylation GCEP on the meeting date January 3, 2024 (SOP Version 10). ","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/5dc53c97-cb65-4d12-bb90-9240391ac024","GCISnapshot":"https://genegraph.clinicalgenome.org/r/7bc60daf-72c4-4a3f-9d1c-96bffd8a9bc9","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/7bc60daf-72c4-4a3f-9d1c-96bffd8a9bc9_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10135","date":"2024-02-06T20:08:31.649Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/7bc60daf-72c4-4a3f-9d1c-96bffd8a9bc9_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10135","date":"2024-02-06T17:00:00.000Z","role":"Approver"}],"curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7bc60daf-72c4-4a3f-9d1c-96bffd8a9bc9_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7bc60daf-72c4-4a3f-9d1c-96bffd8a9bc9_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f4a5e1e5-c0ce-40c9-83d3-fd13760180ad","type":"EvidenceLine","dc:description":"Both variants used to generated an inducible FGF23 transgenic mouse expressing human mutant FGF23 (R176Q and R179Q) found in patients with autosomal dominant hypophosphatemic rickets (ADHR) [AR of GALNT3) were both pathogenic variants ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/564be00a-edc7-463c-bbb8-2f43b2d168b1","type":"Finding","dc:description":"The addition of an ADHR mutation (in the form of transgene or knock-in) in the human FGF23 or mouse Fgf23 SPC site on the Galnt3-null background eliminated the need for FGF23/Fgf23 O-glycosylation by ppGalNAc-T3 and reversed the hyperphosphatemic phenotype of the tumoral calcinosis model. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25051439","rdfs:label":"Genetic Rescue of Glycosylation-deficient Fgf23 in the Galnt","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2.5},{"id":"https://genegraph.clinicalgenome.org/r/b036314e-ee49-4890-966d-7929c09fd777","type":"EvidenceLine","dc:description":"Galnt3-deficient mice provide in vivo evidence that Galnt3 plays an essential role in proper secretion of Fgf23. This evidence has been consistent throughout patient/proband evidence as well. ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bad79285-1d29-4692-b323-d8cb59a6bc74","type":"Finding","dc:description":"Consistent with common phenotypes in patients with GALNT3 mutation. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19213845","rdfs:label":"Galnt3 Gene Leads to Low-Circulating Intact Fibroblast Growt","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2.5}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/7bc60daf-72c4-4a3f-9d1c-96bffd8a9bc9_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d7f1965e-0b20-435e-94d2-0a225cf31bf6","type":"EvidenceLine","dc:description":"Consistent throughout research and patient studies. ","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1ead6f95-2467-4e81-af3a-5f8fed84535a","type":"Finding","dc:description":"Fibroblast growth factor 23 (FGF23) requires O-glycosylation, and that GalNAc-T3 selectively directs O-glycosylation in a proprotein convertase recognition sequence, which blocks processing of FGF23. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16638743","rdfs:label":"fibroblast growth factor 23 (FGF23) requires O-glycosylation","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":5},{"id":"https://genegraph.clinicalgenome.org/r/7bc60daf-72c4-4a3f-9d1c-96bffd8a9bc9_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/42b0fdce-5f5e-4c74-a98a-6efc1e30f52f_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/40b354ae-0cc1-4b18-a775-3cd084a8de9f","type":"EvidenceLine","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/40b354ae-0cc1-4b18-a775-3cd084a8de9f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20358599","allele":{"id":"https://genegraph.clinicalgenome.org/r/86ca60b2-d579-436c-ae3d-05461b09cf2e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004482.4(GALNT3):c.677del (p.Ala226ValfsTer3)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA212884"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/42b0fdce-5f5e-4c74-a98a-6efc1e30f52f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20358599","rdfs:label":"Ichikawa 2010 Patient 2","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":5,"allele":{"id":"https://genegraph.clinicalgenome.org/r/86ca60b2-d579-436c-ae3d-05461b09cf2e"},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypeFreeText":"Swelling over the long bones.\n","phenotypes":["obo:HP_0001945","obo:HP_0012531"],"previousTesting":false,"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/40b354ae-0cc1-4b18-a775-3cd084a8de9f_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/7bc60daf-72c4-4a3f-9d1c-96bffd8a9bc9_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0b22d35e-2215-4f24-bbe2-6609d32b0389_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15133511","rdfs:label":"Topaz Family 1","family":{"id":"https://genegraph.clinicalgenome.org/r/0b22d35e-2215-4f24-bbe2-6609d32b0389","type":"Family","rdfs:label":"Topaz Family 1","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/6234daf6-7f35-49a4-bcd4-84919ce1c86d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15133511","rdfs:label":"Topaz Proband 1","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":4,"allele":{"id":"https://genegraph.clinicalgenome.org/r/27cbca03-632d-4901-855a-d8b89a038b8f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004482.4(GALNT3):c.1524+1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA212877"}},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypeFreeText":"Affected members had large calcified masses that interfered with hip joints.","phenotypes":"obo:HP_0002905","previousTesting":true,"previousTestingDescription":"Identified 11 genes associated with FTC, B3GALT1, SCN7A, SCN9A, SCN1A and STK39 have roles in neural or neuroendocrine tissues; the functions of TAIP-2, CMYA3, FLJ11457, LOC90643 and LASS6 are mostly unknown.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/018f168c-f1a6-4365-b1c7-86c1940d91e8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15133511","allele":{"id":"https://genegraph.clinicalgenome.org/r/27cbca03-632d-4901-855a-d8b89a038b8f"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}}},"phenotypeFreeText":"Affected members had large calcified masses that interfered with hip joints.","phenotypePositiveAllelePositive":5,"phenotypes":"obo:HP_0002905","proband":{"id":"https://genegraph.clinicalgenome.org/r/6234daf6-7f35-49a4-bcd4-84919ce1c86d"}},{"id":"https://genegraph.clinicalgenome.org/r/17ea5241-bd37-4fcf-b9e3-383bfe1b807a_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15133511","rdfs:label":"Topaz Family 2","family":{"id":"https://genegraph.clinicalgenome.org/r/17ea5241-bd37-4fcf-b9e3-383bfe1b807a","type":"Family","rdfs:label":"Topaz Family 2","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/893714ad-cb76-4a6f-b34e-aaf99e14d2c9","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15133511","rdfs:label":"Topaz Proband 2","allele":[{"id":"https://genegraph.clinicalgenome.org/r/9c8a9486-f3d0-401b-a682-cf4147804906","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004482.4(GALNT3):c.1524+5G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA212878"}},{"id":"https://genegraph.clinicalgenome.org/r/aac06260-bfdf-4768-afba-75e87fddbfe9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004482.4(GALNT3):c.484C>T (p.Arg162Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA119079"}}],"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypes":"obo:HP_0002905","previousTesting":true,"previousTestingDescription":"\nIdentified 11 genes associated with FTC, B3GALT1, SCN7A, SCN9A, SCN1A and STK39 have roles in neural or neuroendocrine tissues; the functions of TAIP-2, CMYA3, FLJ11457, LOC90643 and LASS6 are mostly unknown.\n","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/76fd2261-ea72-4160-97bb-0e394c3fbb40_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15133511","allele":{"id":"https://genegraph.clinicalgenome.org/r/9c8a9486-f3d0-401b-a682-cf4147804906"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/b634ebbd-d602-4588-a35c-e2ed2b9e6056_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15133511","allele":{"id":"https://genegraph.clinicalgenome.org/r/aac06260-bfdf-4768-afba-75e87fddbfe9"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]}},"phenotypePositiveAllelePositive":6,"phenotypes":"obo:HP_0002905","proband":{"id":"https://genegraph.clinicalgenome.org/r/893714ad-cb76-4a6f-b34e-aaf99e14d2c9"}},{"id":"https://genegraph.clinicalgenome.org/r/24c4f247-9252-4c6b-a078-337f557749e6_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15687324","rdfs:label":"Ichikawa Family 1","estimatedLodScore":1.83,"family":{"id":"https://genegraph.clinicalgenome.org/r/24c4f247-9252-4c6b-a078-337f557749e6","type":"Family","rdfs:label":"Ichikawa Family 1","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/684278c6-9e8d-4bbd-a9ea-253069b49811","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15687324","rdfs:label":"Ichikawa Proband 1","allele":[{"id":"https://genegraph.clinicalgenome.org/r/35565302-33d3-4904-8c51-c35ee6dc2154","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004482.4(GALNT3):c.516-2A>T","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA212880"}},{"id":"https://genegraph.clinicalgenome.org/r/aac06260-bfdf-4768-afba-75e87fddbfe9"}],"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypeFreeText":"Classical manifestations of tumoral calcinosis, including tumorous calcific masses, hyperphosphatemia [range 5.50–7.30 mg/dl","phenotypes":["obo:HP_0000164","obo:HP_0002905","obo:HP_0003771"],"previousTesting":true,"previousTestingDescription":"Gene expression of GALNT3 and FGF23 genes was assessed by RT-PCR analysis","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/97a4041b-7e37-4929-bf45-6ffe4fc9d4d3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15687324","allele":{"id":"https://genegraph.clinicalgenome.org/r/aac06260-bfdf-4768-afba-75e87fddbfe9"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/fac63183-2d51-47cd-9411-8aeaebfa6ef6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15687324","allele":{"id":"https://genegraph.clinicalgenome.org/r/35565302-33d3-4904-8c51-c35ee6dc2154"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}]}},"phenotypeFreeText":"Classical manifestations of tumoral calcinosis, including tumorous calcific masses, hyperphosphatemia [range 5.50–7.30 mg/dl","phenotypeNegativeAlleleNegative":5,"phenotypePositiveAllelePositive":3,"phenotypes":["obo:HP_0003771","obo:HP_0002905","obo:HP_0000164"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/684278c6-9e8d-4bbd-a9ea-253069b49811"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/6234daf6-7f35-49a4-bcd4-84919ce1c86d_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/018f168c-f1a6-4365-b1c7-86c1940d91e8","type":"EvidenceLine","dc:description":"Phenotypic evidence is not described and is not sufficiently specific","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/018f168c-f1a6-4365-b1c7-86c1940d91e8_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/6234daf6-7f35-49a4-bcd4-84919ce1c86d"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/893714ad-cb76-4a6f-b34e-aaf99e14d2c9_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/76fd2261-ea72-4160-97bb-0e394c3fbb40","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/76fd2261-ea72-4160-97bb-0e394c3fbb40_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/b634ebbd-d602-4588-a35c-e2ed2b9e6056","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b634ebbd-d602-4588-a35c-e2ed2b9e6056_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/893714ad-cb76-4a6f-b34e-aaf99e14d2c9"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/684278c6-9e8d-4bbd-a9ea-253069b49811_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fac63183-2d51-47cd-9411-8aeaebfa6ef6","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fac63183-2d51-47cd-9411-8aeaebfa6ef6_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/97a4041b-7e37-4929-bf45-6ffe4fc9d4d3","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/97a4041b-7e37-4929-bf45-6ffe4fc9d4d3_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/684278c6-9e8d-4bbd-a9ea-253069b49811"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/2fce6264-891d-4350-8d61-e025dc4809b7_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9c51e2d0-56ad-4dfa-9994-9dfded020423","type":"EvidenceLine","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9c51e2d0-56ad-4dfa-9994-9dfded020423_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20358599","allele":{"id":"https://genegraph.clinicalgenome.org/r/4e781e8a-4184-403b-b0c1-f6ebe4d227be","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004482.4(GALNT3):c.1626+1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA212883"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/2fce6264-891d-4350-8d61-e025dc4809b7","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20358599","rdfs:label":"Ichikawa 2010 Patient 3","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":15,"allele":{"id":"https://genegraph.clinicalgenome.org/r/4e781e8a-4184-403b-b0c1-f6ebe4d227be"},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypes":["obo:HP_0030838","obo:HP_0001288"],"previousTesting":false,"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/9c51e2d0-56ad-4dfa-9994-9dfded020423_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/d9dd63b7-ae5c-499a-aead-ecde73b560af_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/220a3d91-7e0f-47a9-8bfd-763440e64a07","type":"EvidenceLine","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/220a3d91-7e0f-47a9-8bfd-763440e64a07_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20358599","allele":{"id":"https://genegraph.clinicalgenome.org/r/d081c569-35b9-4be4-b346-76fcc287981d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004482.4(GALNT3):c.485G>A (p.Arg162Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1941232"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/d9dd63b7-ae5c-499a-aead-ecde73b560af","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20358599","rdfs:label":"Ichikawa 2010 Patient 1","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":13,"allele":{"id":"https://genegraph.clinicalgenome.org/r/d081c569-35b9-4be4-b346-76fcc287981d"},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypeFreeText":"Presented with a painful firm mass over the left lateral gluteal region, which was surgically excised. ","phenotypes":"obo:HP_0002905","previousTesting":false,"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/220a3d91-7e0f-47a9-8bfd-763440e64a07_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":7773,"specifiedBy":"GeneValidityCriteria10","strengthScore":17,"subject":{"id":"https://genegraph.clinicalgenome.org/r/N86MA3GC3zo","type":"GeneValidityProposition","disease":"obo:MONDO_0100252","gene":"hgnc:4125","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_7bc60daf-72c4-4a3f-9d1c-96bffd8a9bc9-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}